Clinical trials
catalyst calendar across sponsors →Studies where RNA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 9 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, Schonfeld Strategic Advisors LLC, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, +4 more) · FINRA short interest 28.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ATR 1072 in Participants With PRKAG2 SyndromeNCT07738107Incidence of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: ATR 1072 | Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome | 37 | May 2028 | ≤ 651 d | 2026-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19